Company intelligence / Profile preview

Citryll

Oss, Netherlandscitryll.com ↗
Ownership
Private
Development stage
Other
01

Overview

Citryll recently completed first-in-human Phase 1 trials including successful repeat dosing of rheumatoid arthritis patients. Phase 2a trials are planned in both RA and hidradenitis suppurativa

Therapeutic areas
ImmunologyDermatology
Modalities
Monoclonal antibodies
Industry
Biotech
02

Drug pipeline

2 assets

CIT013

2

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Citryll.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Citryll.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call